Literature DB >> 32729651

MicroRNAs and gene regulation in breast cancer.

Fatma Abdalla1, Bhupendra Singh1,2, Hari K Bhat1.   

Abstract

MicroRNAs (miRs) are non-protein-coding small RNAs that control the gene expression posttranscriptionally. miRs can regulate different cellular functions as well as many pathological conditions. Dysregulated miR expression profiles have been identified in different cancer types including lung cancer, breast cancer, and prostate cancer. The expression of miRs varies according to their roles in each specific cancer type. Although many miRs and their target genes have been identified in different cancers, data are still scant to validate those target genes and the mechanistic role of these miRs. The possibility of targeting cancer-associated miRs is suggested to open a new field for cancer therapy. Therapeutic strategies targeting miRs involve neutralization of the oncogenic miRs by antagomirs using locked nucleic acid oligonucleotides, miR sponges, or the restoration/overexpression of tumor-suppressing miRs that are downregulated or depleted in cancers. Although it is suggested that therapeutic applications of miRs in different pathological conditions will make a huge revolution in gene therapy, there is still an enormous challenge in employing these strategies efficiently in cancer inhibition, seemingly, due to the complexity of cancer and the current inefficient development of delivery systems for the therapeutic miRs.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  TS-miR; breast cancer; cancer therapy; microRNA; oncomir

Mesh:

Substances:

Year:  2020        PMID: 32729651     DOI: 10.1002/jbt.22567

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  5 in total

1.  Genome-Wide Analysis of microRNA and mRNA Expression in Colorectal Intramucosal Neoplasia and Colorectal Cancer With a Microsatellite-Stable Phenotype Based on Adenoma-Carcinoma Sequences.

Authors:  Tamotsu Sugai; Mitsumasa Osakabe; Takeshi Niinuma; Ryo Sugimoto; Makoto Eizuka; Yoshihito Tanaka; Naoki Yanagawa; Koki Otsuka; Akira Sasaki; Takayuki Matsumoto; Hiromu Suzuki
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

2.  Long non-coding RNA A1BG-AS1 promotes tumorigenesis in breast cancer by sponging microRNA-485-5p and consequently increasing expression of FLOT1 expression.

Authors:  Shibin Cai; Yi Zhou; Ying Pan; Pengpeng Liu; Kaijie Yu; Shuzheng Chen
Journal:  Hum Cell       Date:  2021-06-11       Impact factor: 4.174

3.  The local anesthetic ropivacaine suppresses progression of breast cancer by regulating miR-27b-3p/YAP axis.

Authors:  Lu Zhao; Shuang Han; Junde Hou; Wenhui Shi; Yonglei Zhao; Yongxue Chen
Journal:  Aging (Albany NY)       Date:  2021-06-14       Impact factor: 5.682

4.  In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy.

Authors:  Viktor Maurer; Selin Altin; Didem Ag Seleci; Ajmal Zarinwall; Bilal Temel; Peter M Vogt; Sarah Strauß; Frank Stahl; Thomas Scheper; Vesna Bucan; Georg Garnweitner
Journal:  Pharmaceutics       Date:  2021-03-16       Impact factor: 6.321

Review 5.  MicroRNAs as a clue to overcome breast cancer treatment resistance.

Authors:  Iris Garrido-Cano; Birlipta Pattanayak; Anna Adam-Artigues; Ana Lameirinhas; Sandra Torres-Ruiz; Eduardo Tormo; Raimundo Cervera; Pilar Eroles
Journal:  Cancer Metastasis Rev       Date:  2021-09-15       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.